The first clinical trial demonstrating the benefits of Remogen Omega has been published!We are proud to announce that the results of the REMOTOP study (a multicentre study on topical omega-3 fatty acids (REMOGEN® OMEGA) in the treatment of dry eye) have been published in Clinical Ophthalmology this month.
Summary of the study
This randomised, masked-observer study compared the efficacy of topical omega-3 polyunsaturated fatty acids (Remogen Omega) and povidone (Wet-Comod) in patients suffering from moderate to severe dry eye disease. The primary objective of this study was met, demonstrating that Remogen Omega is non-inferior to 2% povidone both for the increase of the Tear Break-Up Time and the improvement of the Ocular Surface Disease Index after 4 weeks of treatment.
At Week 4 and 12, both treatments resulted in a significant improvement of most secondary endpoints (clinical global impression, conjunctival and corneal staining, tear film volume), often with a numerical but not statistically significant difference in favour of Remogen Omega. Beyond statistical significance, only the improvements observed with Remogen Omega exceeded the threshold of minimal clinically important differences (MCID).
Interestingly, the use of Remogen Omega appears to reduce the prevalence of elevated MMP-9 (matrix metalloproteinase 9) concentration in the tear film. Although preliminary, these data might indicate that Remogen Omega inhibits the inflammatory processes of the ocular surface.
Both treatments were well tolerated and no safety issue was identified.
• Remogen Omega improves the signs and symptoms of dry eye disease for at least 3 months.
• Preliminary NEW data indicate that Remogen Omega might inhibit the inflammation at the ocular surface, contributing to break the vicious circle of dry eye disease.
• The topical application of omega-3 fatty acids directly on the ocular surface is an effective alternative to the use of omega-3 food supplements.
These results confirm Remogen Omega as a valid solution for the treatment of moderate to severe dry eye disease.
For the full article go to https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9744874/